Plain-English translation of NCT06896422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing whether —a natural compound your body already makes—can help improve the effectiveness of standard lung cancer treatment when combined with a type of immunotherapy drug (a PD-1 inhibitor) and . Researchers believe may help boost your immune system's ability to fight the cancer. The study will compare patients who receive the standard treatment alone versus those who receive the standard treatment plus .
Current lung cancer treatments work well for some patients, but many others see their cancer return or progress after initial therapy. Scientists have discovered that may strengthen the immune system's response to cancer, so this trial aims to see whether adding it to existing treatments can help more patients benefit and survive longer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups: one group receives the standard immunotherapy drug plus , and the other group receives the same treatment plus added to it. You will need to visit the hospital regularly for infusions, blood tests, and imaging scans to monitor how you're responding. The study is enrolling about 80 patients total and will track your health and cancer progression over time.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China